Search results for "Diabetic nephropathy"

showing 10 items of 34 documents

Effects of an Antimutagenic 1,4-Dihydropyridine AV-153 on Expression of Nitric Oxide Synthases and DNA Repair-related Enzymes and Genes in Kidneys of…

2016

Development of complications of diabetes mellitus (DM), including diabetic nephropathy, is a complex multi-stage process, dependent on many factors including the modification of nitric oxide (NO) production and an impaired DNA repair. The goal of this work was to study in vivo effects of 1,4-dihydropyridine AV-153, known as antimutagen and DNA binder, on the expression of several genes and proteins involved in NO metabolism and DNA repair in the kidneys of rats with a streptozotocin (STZ)-induced model of DM. Transcription intensity was monitored by means of real-time RT-PCR and the expression of proteins by immunohistochemistry. Development of DM significantly induced PARP1 protein express…

0301 basic medicineMalemedicine.medical_specialtyDihydropyridinesDNA RepairNitric Oxide Synthase Type IIIDNA repairPoly (ADP-Ribose) Polymerase-1Gene ExpressionNitric Oxide Synthase Type II030204 cardiovascular system & hematologyToxicologyKidneyNiacinStreptozocinNitric oxideDiabetes Mellitus ExperimentalDiabetic nephropathyHistones03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosInternal medicineGene expressionmedicineAnimalsRNA MessengerRats WistarGenePharmacologybiologyReverse Transcriptase Polymerase Chain ReactionKidney metabolismAntimutagenic AgentsGeneral Medicinemedicine.diseaseStreptozotocinbiology.organism_classificationPhosphoproteinsMolecular biologyRats030104 developmental biologyEndocrinologychemistrymedicine.drugBasicclinical pharmacologytoxicology
researchProduct

The anti-oxidative role of cytoglobin in podocytes: implications for a role in chronic kidney disease

2020

Abstract: Aims: Cytoglobin (CYGB) is a member of the mammalian globin family of respiratory proteins. Despite extensive research efforts, its physiological role remains largely unknown, but potential functions include reactive oxygen species (ROS) detoxification and signaling. Accumulating evidence suggests that ROS play a crucial role in podocyte detachment and apoptosis during diabetic kidney disease. This study aimed to explore the potential antioxidative renal role of CYGB both in vivo and in vitro. Results: Using a Cygb-deficient mouse model, we demonstrate a Cygb-dependent reduction in renal function, coinciding with a reduced number of podocytes. To specifically assess the putative a…

0301 basic medicineProgrammed cell death1303 BiochemistryCell SurvivalPhysiologyClinical Biochemistry610 Medicine & healthBiology1308 Clinical Biochemistrymedicine.disease_causeBiochemistryAntioxidantsPodocyteNephropathy10052 Institute of PhysiologyTranscriptomeDiabetic nephropathy1307 Cell Biology03 medical and health sciencesMicemedicine1312 Molecular BiologyAnimalsHumansRenal Insufficiency ChronicBiologyMolecular BiologyCells CulturedGeneral Environmental ScienceMice KnockoutGene knockdown030102 biochemistry & molecular biologyPodocytesCytoglobinCytoglobin1314 PhysiologyCell Biologymedicine.diseaseCell biologyMice Inbred C57BLChemistryDisease Models Animal030104 developmental biologymedicine.anatomical_structureGeneral Earth and Planetary Sciences570 Life sciences; biologyHuman medicineOxidative stress
researchProduct

Mitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients

2018

The association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T&gt

0301 basic medicinemedicine.medical_specialtyendocrine system diseasesgenetic structurestype 2 diabetes mellituslcsh:MedicineRenal functionType 2 diabetesArticleHaplogroupNephropathyDiabetic nephropathy03 medical and health scienceschemistry.chemical_compoundInternal medicineMedicineCreatininebusiness.industrymtDNAlcsh:Rmitochondrial haplogroupType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseeye diseaseshumanities030104 developmental biologyEndocrinologychemistryglycemic controlnephropathybusinessHuman mitochondrial DNA haplogroup
researchProduct

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what …

2019

Albuminuria; Atrasentan; Canagliflozin Albuminuria; Atrasentan; Canagliflozina Albuminúria; Atrasentan; Canagliflozina In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. Both trials demonstrated significant nephroprot…

:compuestos heterocíclicos::compuestos heterocíclicos de 1 anillo::dioxoles::benzodioxoles::atrasentán [COMPUESTOS QUÍMICOS Y DROGAS]030232 urology & nephrologysodium-glucose cotransporter-2 (SGLT2) inhibitor:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Diabetic nephropathychemistry.chemical_compound0302 clinical medicineChronic kidney diseaseClinical endpointNefropaties diabètiques - Tractament:Other subheadings::/therapeutic use [Other subheadings]canagliflozin:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]CanagliflozinSglt2 Inhibitors:enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES]Sodium-glucose cotransporter-2 (SGLT2) inhibitorNephrologyendothelinmedicine.drugmedicine.medical_specialty:hidratos de carbono::glicósidos::glucósidos::canagliflozina [COMPUESTOS QUÍMICOS Y DROGAS]UrologyRenal functionalbuminuriaEndothelinNephropathy:Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES]03 medical and health sciencesmedicineAlbuminuriaPirrolidina - Ús terapèutic:Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Dioxoles::Benzodioxoles::Atrasentan [CHEMICALS AND DRUGS]CanagliflozinDiabetic kidney diseaseTransplantationCreatinine:Carbohydrates::Glycosides::Glucosides::Canagliflozin [CHEMICALS AND DRUGS]atrasentan:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryAtrasentanGlucòsids - Ús terapèuticmedicine.diseasediabetic kidney diseasechemistryAtrasentanbusinesschronic kidney diseaseKidney disease
researchProduct

Ten Years of Simultaneous Pancreas-Kidney Transplantation: A Retrospective Single-Center Analysis of Prospectively Obtained Data

2011

Simultaneous pancreas-kidney transplantation (SPK) is a standardized and life-saving procedure for a patient suffering from both insulin-dependent diabetes mellitus type 1 (IDDM 1) and end-stage diabetic nephropathy. To expand the donor pool and to determine the influence of the preprocurement pancreas suitability scoring system (P-PASS) on pancreas graft survival we retrospectively analyzed our data on SPK.From 1999 to 2010 we performed 55 SPKs, using systemic-enteric drainage as surgical approach. The immunosuppressive therapy was induced with basiliximab; maintenance therapy was based on tacrolimus, mycophenolate mofetil, and steroids. Data were prospectively obtained, analyzed, and corr…

AdultGraft RejectionMalemedicine.medical_specialtyScoring systemCell SurvivalSingle CenterBody Mass IndexDiabetic nephropathyDiabetes mellitusmedicineHumansDiabetic NephropathiesProspective StudiesDonor poolRetrospective StudiesTransplantationbusiness.industryGraft SurvivalSimultaneous pancreas kidney transplantationMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationDiabetes Mellitus Type 1Treatment Outcomemedicine.anatomical_structureFemaleSurgeryPancreas TransplantationPancreasbusinessImmunosuppressive AgentsTransplantation Proceedings
researchProduct

Insulin-dependent diabetes mellitus and glycosaminoglycans.

1995

The influence of diabetic nephropathy on urinary glycosaminoglycan distribution was assessed in 96 patients with insulin-dependent diabetes mellitus (IDDM, 49 female, age: 16 - 64 yrs, median 35; duration of IDDM: 0 - 43 yrs, median 13 yrs) in comparison to 103 healthy controls (57 female, 17 - 82 yrs, median 40 yrs). Glycosaminoglycan concentration of 24 h urine samples was determined by means of precipitation with cethylpyridinium chloride and potassium acetate in ethanol followed by a colorimetric test with carbazole. A marked difference (p = 0.0008) in urinary glycosaminoglycan excretion between patients (19.0, 12.4, 35.6 mg/24 h, median, 25th, 75th percentile) and controls (15.8, 10.4,…

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismUrinary systemClinical BiochemistryBiochemistryNephropathyDiabetic nephropathyExcretionGlycosaminoglycanEndocrinologyDiabetes mellitusInternal medicinemedicineHumansDiabetic NephropathiesAgedGlycosaminoglycansAged 80 and overDiabetic Retinopathybusiness.industryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseUrinary glycosaminoglycan excretionEndocrinologyDiabetes Mellitus Type 1FemalebusinessRetinopathyHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Angiopoietin 2 and Neuropeptide Y are Associated with Diabetic Kidney Disease in Type 1 Diabetes Mellitus

2020

Abstract Background Serum angiopoietin 2 levels have been associated with endothelial dysfunction and diabetic kidney disease. Derangements in autonomous nervous system lead to increased production of vasoconstrictory and angiogenic mediators such as norepinephrine and neuropeptide Y and are associated with increased risk of microvascular complications. Aim To investigate associations between angiopoietin 2, neuropeptide Y and diabetic kidney disease in patients with type 1 diabetes mellitus. Methods 289 patients with type 1 diabetes mellitus duration > 1 year were included. Patients were stratified according to presence of diabetic nephropathy (macroalbuminuria, estimated glomerular fil…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRenal functionDiseaseAngiopoietin-2Norepinephrine (medication)Diabetic nephropathyEndocrinologyInternal medicineInternal MedicinemedicineHumansDiabetic NephropathiesNeuropeptide YEndothelial dysfunctionType 1 diabetesbusiness.industryGeneral MedicineStepwise regressionmedicine.diseaseNeuropeptide Y receptorDiabetes Mellitus Type 1EndocrinologyHypertensionFemalebusinessBiomarkersGlomerular Filtration Ratemedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease

2018

OBJECTIVE The effect of pentoxifylline on Klotho levels in patients with type 2 diabetes mellitus with chronic kidney disease (CKD) was assessed in a post hoc analysis of the Pentoxifylline for Renoprotection in Diabetic Nephropathy (PREDIAN) trial. RESEARCH DESIGN AND METHODS Circulating and urinary tumor necrosis factor-α (TNF-α) and Klotho were measured before and after 1 year of pentoxifylline. The effect on Klotho expression was assessed in cultured renal tubular cells. RESULTS Pentoxifylline administration resulted in decreased serum and urinary TNF-α, whereas serum and urinary Klotho increased significantly. Changes in urinary Klotho, urinary TNF-α, and phosphorus were associated wi…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismUrinary system030232 urology & nephrologyRenal function030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesPentoxifyllineDiabetic nephropathyMice03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineAlbuminuriaAnimalsHumansMedicineDiabetic NephropathiesPentoxifyllineRenal Insufficiency ChronicKlotho ProteinsKlothoCells CulturedAgedGlucuronidaseAdvanced and Specialized NursingTumor Necrosis Factor-alphabusiness.industryKidney metabolismMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsKidney TubulesEndocrinologyDiabetes Mellitus Type 2AlbuminuriaFemalemedicine.symptombusinessFollow-Up StudiesGlomerular Filtration RateKidney diseasemedicine.drugDiabetes Care
researchProduct

Morbidity in 565 Type 2 Diabetic Patients According to Stage of Nephropathy

1998

Between 1988 and 1992, 565 type 2 diabetic patients were examined for nephropathy and diabetes-associated diseases during hospital treatment. Stages of nephropathy were defined as no clinical sign of nephropathy (N = 280), microalbuminuria (N = 38), overt proteinuria (N = 105), impaired renal function (N = 55), and chronic dialysis therapy (N = 87). In dialyzed patients, HbA1c averaged 6.8%, and, in the other groups, HbA1c was between 7.6% and 8.3% (normal range, 3.8%-6.1%). Cataract was not associated with the severity of nephropathy. Stroke was most common in the stage of renal insufficiency (34%). The following complications, as found in medical history or as current event, showed a sign…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMyocardial InfarctionBlood PressureGastroenterologyNephropathyCohort StudiesDiabetic nephropathyEndocrinologyRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineAlbuminuriaHumansCarotid StenosisDiabetic NephropathiesRenal replacement therapyAgedDiabetic RetinopathyProteinuriabusiness.industryMiddle Agedmedicine.diseaseSurgeryRenal Replacement TherapyCerebrovascular DisordersProteinuriaDiabetes Mellitus Type 2HypertensionAlbuminuriaFemaleHypertrophy Left VentricularMicroalbuminuriaMorbiditymedicine.symptombusinessKidney diseaseJournal of Diabetes and its Complications
researchProduct

Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.

2011

Our aim was to investigate u-NGAL, u-KIM1 and p-FGF23 and prediction of decline in kidney function in type 2 diabetic patients with proteinuria.We performed a follow-up study, follow-up median (range) 3.5 (1-5) years. At baseline u-NGAL, u-KIM1 and p-FGF23 (ELISA) was measured and patients were followed yearly with estimated(e)-GFR (MDRD) and u-albumin.We included 177 patients (44 women), mean age (SD) 59 (9) years. eGFR 90 (24) ml/min/1.73 m(2) at baseline, u-albumin: median (interquartile range) 104 (39-238) mg/24 h. Patients with levels of u-KIM1 in the highest quartile had a greater decline in eGFR than patients with the lowest quartile 6.0 (5.4) versus 3.2 (5.5) ml/min/1.73 m(2) per ye…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesKidneyEnd stage renal diseaseDiabetic nephropathyEndocrinologyInterquartile rangeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansDiabetic NephropathiesProteinuriabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseFibroblast Growth Factor-23ProteinuriaEndocrinologyKidney TubulesQuartileDiabetes Mellitus Type 2Disease ProgressionFemalemedicine.symptombusinessBiomarkersAcute-Phase ProteinsFollow-Up StudiesGlomerular Filtration RateDiabetes research and clinical practice
researchProduct